img

Global Oncology (Anti-cancer Drugs) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oncology (Anti-cancer Drugs) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Oncology (Anti-cancer Drugs) market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Oncology (Anti-cancer Drugs) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Oncology (Anti-cancer Drugs) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Oncology (Anti-cancer Drugs) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Oncology (Anti-cancer Drugs) include Roche, Novartis, Celgene, Amgen, Johnson & Johnson, GlaxoSmithKline, Eli lilly & Co, Pfizer and Merck & Co., etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Oncology (Anti-cancer Drugs), the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Oncology (Anti-cancer Drugs) by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Oncology (Anti-cancer Drugs) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Oncology (Anti-cancer Drugs) market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Roche
Novartis
Celgene
Amgen
Johnson & Johnson
GlaxoSmithKline
Eli lilly & Co
Pfizer
Merck & Co.
Sanofi
By Type
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Others
By Application
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Oncology (Anti-cancer Drugs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Oncology (Anti-cancer Drugs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology (Anti-cancer Drugs) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Oncology (Anti-cancer Drugs) Definition
1.2 Market by Type
1.2.1 Global Oncology (Anti-cancer Drugs) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Blood Cancer
1.2.3 Breast Cancer
1.2.4 Gastrointestinal Cancer
1.2.5 Prostate Cancer
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Oncology (Anti-cancer Drugs) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Chemotherapy
1.3.3 Targeted Therapy
1.3.4 Immunotherapy (Biologic Therapy)
1.3.5 Hormonal Therapy
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Oncology (Anti-cancer Drugs) Sales
2.1 Global Oncology (Anti-cancer Drugs) Revenue Estimates and Forecasts 2018-2034
2.2 Global Oncology (Anti-cancer Drugs) Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Oncology (Anti-cancer Drugs) Revenue by Region
2.3.1 Global Oncology (Anti-cancer Drugs) Revenue by Region (2018-2024)
2.3.2 Global Oncology (Anti-cancer Drugs) Revenue by Region (2024-2034)
2.4 Global Oncology (Anti-cancer Drugs) Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Oncology (Anti-cancer Drugs) Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Oncology (Anti-cancer Drugs) Sales Quantity by Region
2.6.1 Global Oncology (Anti-cancer Drugs) Sales Quantity by Region (2018-2024)
2.6.2 Global Oncology (Anti-cancer Drugs) Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Oncology (Anti-cancer Drugs) Sales Quantity by Manufacturers
3.1.1 Global Oncology (Anti-cancer Drugs) Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Oncology (Anti-cancer Drugs) Sales in 2022
3.2 Global Oncology (Anti-cancer Drugs) Revenue by Manufacturers
3.2.1 Global Oncology (Anti-cancer Drugs) Revenue by Manufacturers (2018-2024)
3.2.2 Global Oncology (Anti-cancer Drugs) Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oncology (Anti-cancer Drugs) Revenue in 2022
3.3 Global Oncology (Anti-cancer Drugs) Sales Price by Manufacturers
3.4 Global Key Players of Oncology (Anti-cancer Drugs), Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oncology (Anti-cancer Drugs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oncology (Anti-cancer Drugs), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oncology (Anti-cancer Drugs), Product Offered and Application
3.8 Global Key Manufacturers of Oncology (Anti-cancer Drugs), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Oncology (Anti-cancer Drugs) Sales Quantity by Type
4.1.1 Global Oncology (Anti-cancer Drugs) Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Oncology (Anti-cancer Drugs) Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
4.2 Global Oncology (Anti-cancer Drugs) Revenue by Type
4.2.1 Global Oncology (Anti-cancer Drugs) Historical Revenue by Type (2018-2024)
4.2.2 Global Oncology (Anti-cancer Drugs) Forecasted Revenue by Type (2024-2034)
4.2.3 Global Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
4.3 Global Oncology (Anti-cancer Drugs) Price by Type
4.3.1 Global Oncology (Anti-cancer Drugs) Price by Type (2018-2024)
4.3.2 Global Oncology (Anti-cancer Drugs) Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Oncology (Anti-cancer Drugs) Sales Quantity by Application
5.1.1 Global Oncology (Anti-cancer Drugs) Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Oncology (Anti-cancer Drugs) Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
5.2 Global Oncology (Anti-cancer Drugs) Revenue by Application
5.2.1 Global Oncology (Anti-cancer Drugs) Historical Revenue by Application (2018-2024)
5.2.2 Global Oncology (Anti-cancer Drugs) Forecasted Revenue by Application (2024-2034)
5.2.3 Global Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
5.3 Global Oncology (Anti-cancer Drugs) Price by Application
5.3.1 Global Oncology (Anti-cancer Drugs) Price by Application (2018-2024)
5.3.2 Global Oncology (Anti-cancer Drugs) Price Forecast by Application (2024-2034)
6 North America
6.1 North America Oncology (Anti-cancer Drugs) Sales by Company
6.1.1 North America Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024)
6.1.2 North America Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024)
6.2 North America Oncology (Anti-cancer Drugs) Market Size by Type
6.2.1 North America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2034)
6.2.2 North America Oncology (Anti-cancer Drugs) Revenue by Type (2018-2034)
6.3 North America Oncology (Anti-cancer Drugs) Market Size by Application
6.3.1 North America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2034)
6.3.2 North America Oncology (Anti-cancer Drugs) Revenue by Application (2018-2034)
6.4 North America Oncology (Anti-cancer Drugs) Market Size by Country
6.4.1 North America Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Oncology (Anti-cancer Drugs) Revenue by Country (2018-2034)
6.4.3 North America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Oncology (Anti-cancer Drugs) Sales by Company
7.1.1 Europe Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024)
7.1.2 Europe Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024)
7.2 Europe Oncology (Anti-cancer Drugs) Market Size by Type
7.2.1 Europe Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2034)
7.2.2 Europe Oncology (Anti-cancer Drugs) Revenue by Type (2018-2034)
7.3 Europe Oncology (Anti-cancer Drugs) Market Size by Application
7.3.1 Europe Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2034)
7.3.2 Europe Oncology (Anti-cancer Drugs) Revenue by Application (2018-2034)
7.4 Europe Oncology (Anti-cancer Drugs) Market Size by Country
7.4.1 Europe Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Oncology (Anti-cancer Drugs) Revenue by Country (2018-2034)
7.4.3 Europe Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Oncology (Anti-cancer Drugs) Sales by Company
8.1.1 China Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024)
8.1.2 China Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024)
8.2 China Oncology (Anti-cancer Drugs) Market Size by Type
8.2.1 China Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2034)
8.2.2 China Oncology (Anti-cancer Drugs) Revenue by Type (2018-2034)
8.3 China Oncology (Anti-cancer Drugs) Market Size by Application
8.3.1 China Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2034)
8.3.2 China Oncology (Anti-cancer Drugs) Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Oncology (Anti-cancer Drugs) Sales by Company
9.1.1 APAC Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024)
9.1.2 APAC Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024)
9.2 APAC Oncology (Anti-cancer Drugs) Market Size by Type
9.2.1 APAC Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2034)
9.2.2 APAC Oncology (Anti-cancer Drugs) Revenue by Type (2018-2034)
9.3 APAC Oncology (Anti-cancer Drugs) Market Size by Application
9.3.1 APAC Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2034)
9.3.2 APAC Oncology (Anti-cancer Drugs) Revenue by Application (2018-2034)
9.4 APAC Oncology (Anti-cancer Drugs) Market Size by Region
9.4.1 APAC Oncology (Anti-cancer Drugs) Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Oncology (Anti-cancer Drugs) Revenue by Region (2018-2034)
9.4.3 APAC Oncology (Anti-cancer Drugs) Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales by Company
10.1.1 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Market Size by Type
10.2.1 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Market Size by Application
10.3.1 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Market Size by Country
10.4.1 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Overview
11.1.3 Roche Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Roche Oncology (Anti-cancer Drugs) Products and Services
11.1.5 Roche Oncology (Anti-cancer Drugs) SWOT Analysis
11.1.6 Roche Recent Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Overview
11.2.3 Novartis Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Novartis Oncology (Anti-cancer Drugs) Products and Services
11.2.5 Novartis Oncology (Anti-cancer Drugs) SWOT Analysis
11.2.6 Novartis Recent Developments
11.3 Celgene
11.3.1 Celgene Company Information
11.3.2 Celgene Overview
11.3.3 Celgene Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Celgene Oncology (Anti-cancer Drugs) Products and Services
11.3.5 Celgene Oncology (Anti-cancer Drugs) SWOT Analysis
11.3.6 Celgene Recent Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Overview
11.4.3 Amgen Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Amgen Oncology (Anti-cancer Drugs) Products and Services
11.4.5 Amgen Oncology (Anti-cancer Drugs) SWOT Analysis
11.4.6 Amgen Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Overview
11.5.3 Johnson & Johnson Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Johnson & Johnson Oncology (Anti-cancer Drugs) Products and Services
11.5.5 Johnson & Johnson Oncology (Anti-cancer Drugs) SWOT Analysis
11.5.6 Johnson & Johnson Recent Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Information
11.6.2 GlaxoSmithKline Overview
11.6.3 GlaxoSmithKline Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 GlaxoSmithKline Oncology (Anti-cancer Drugs) Products and Services
11.6.5 GlaxoSmithKline Oncology (Anti-cancer Drugs) SWOT Analysis
11.6.6 GlaxoSmithKline Recent Developments
11.7 Eli lilly & Co
11.7.1 Eli lilly & Co Company Information
11.7.2 Eli lilly & Co Overview
11.7.3 Eli lilly & Co Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Eli lilly & Co Oncology (Anti-cancer Drugs) Products and Services
11.7.5 Eli lilly & Co Oncology (Anti-cancer Drugs) SWOT Analysis
11.7.6 Eli lilly & Co Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Information
11.8.2 Pfizer Overview
11.8.3 Pfizer Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Pfizer Oncology (Anti-cancer Drugs) Products and Services
11.8.5 Pfizer Oncology (Anti-cancer Drugs) SWOT Analysis
11.8.6 Pfizer Recent Developments
11.9 Merck & Co.
11.9.1 Merck & Co. Company Information
11.9.2 Merck & Co. Overview
11.9.3 Merck & Co. Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Merck & Co. Oncology (Anti-cancer Drugs) Products and Services
11.9.5 Merck & Co. Oncology (Anti-cancer Drugs) SWOT Analysis
11.9.6 Merck & Co. Recent Developments
11.10 Sanofi
11.10.1 Sanofi Company Information
11.10.2 Sanofi Overview
11.10.3 Sanofi Oncology (Anti-cancer Drugs) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Sanofi Oncology (Anti-cancer Drugs) Products and Services
11.10.5 Sanofi Oncology (Anti-cancer Drugs) SWOT Analysis
11.10.6 Sanofi Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Oncology (Anti-cancer Drugs) Value Chain Analysis
12.2 Oncology (Anti-cancer Drugs) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oncology (Anti-cancer Drugs) Production Mode & Process
12.4 Oncology (Anti-cancer Drugs) Sales and Marketing
12.4.1 Oncology (Anti-cancer Drugs) Sales Channels
12.4.2 Oncology (Anti-cancer Drugs) Distributors
12.5 Oncology (Anti-cancer Drugs) Customers
13 Market Dynamics
13.1 Oncology (Anti-cancer Drugs) Industry Trends
13.2 Oncology (Anti-cancer Drugs) Market Drivers
13.3 Oncology (Anti-cancer Drugs) Market Challenges
13.4 Oncology (Anti-cancer Drugs) Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Oncology (Anti-cancer Drugs) Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Blood Cancer
Table 3. Major Manufacturers of Breast Cancer
Table 4. Major Manufacturers of Gastrointestinal Cancer
Table 5. Major Manufacturers of Prostate Cancer
Table 6. Major Manufacturers of Others
Table 7. Global Oncology (Anti-cancer Drugs) Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Oncology (Anti-cancer Drugs) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Oncology (Anti-cancer Drugs) Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Oncology (Anti-cancer Drugs) Revenue Market Share by Region (2018-2024)
Table 11. Global Oncology (Anti-cancer Drugs) Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Oncology (Anti-cancer Drugs) Revenue Market Share by Region (2024-2034)
Table 13. Global Oncology (Anti-cancer Drugs) Sales Quantity by Region: 2018 VS 2022 VS 2034 (K MT)
Table 14. Global Oncology (Anti-cancer Drugs) Sales by Region (2018-2024) & (K MT)
Table 15. Global Oncology (Anti-cancer Drugs) Sales Market Share by Region (2018-2024)
Table 16. Global Oncology (Anti-cancer Drugs) Sales by Region (2024-2034) & (K MT)
Table 17. Global Oncology (Anti-cancer Drugs) Sales Market Share by Region (2024-2034)
Table 18. Global Oncology (Anti-cancer Drugs) Sales Quantity by Manufacturers (2018-2024) & (K MT)
Table 19. Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Manufacturers (2018-2024)
Table 20. Global Oncology (Anti-cancer Drugs) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global Oncology (Anti-cancer Drugs) Revenue Share by Manufacturers (2018-2024)
Table 22. Global Oncology (Anti-cancer Drugs) Price by Manufacturers 2018-2024 (USD/MT)
Table 23. Global Key Players of Oncology (Anti-cancer Drugs), Industry Ranking, 2021 VS 2022
Table 24. Global Oncology (Anti-cancer Drugs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Oncology (Anti-cancer Drugs) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology (Anti-cancer Drugs) as of 2022)
Table 26. Global Key Manufacturers of Oncology (Anti-cancer Drugs), Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Oncology (Anti-cancer Drugs), Product Offered and Application
Table 28. Global Key Manufacturers of Oncology (Anti-cancer Drugs), Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 31. Global Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 32. Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Type (2018-2024)
Table 33. Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Type (2024-2034)
Table 34. Global Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Oncology (Anti-cancer Drugs) Revenue Share by Type (2018-2024)
Table 37. Global Oncology (Anti-cancer Drugs) Revenue Share by Type (2024-2034)
Table 38. Oncology (Anti-cancer Drugs) Price by Type (2018-2024) & (USD/MT)
Table 39. Global Oncology (Anti-cancer Drugs) Price Forecast by Type (2024-2034) & (USD/MT)
Table 40. Global Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 41. Global Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 42. Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Application (2018-2024)
Table 43. Global Oncology (Anti-cancer Drugs) Sales Quantity Share by Application (2024-2034)
Table 44. Global Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Oncology (Anti-cancer Drugs) Revenue Share by Application (2018-2024)
Table 47. Global Oncology (Anti-cancer Drugs) Revenue Share by Application (2024-2034)
Table 48. Oncology (Anti-cancer Drugs) Price by Application (2018-2024) & (USD/MT)
Table 49. Global Oncology (Anti-cancer Drugs) Price Forecast by Application (2024-2034) & (USD/MT)
Table 50. North America Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024) & (US$ Million)
Table 51. North America Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024) & (K MT)
Table 52. North America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 53. North America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 54. North America Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 55. North America Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 57. North America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 58. North America Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 59. North America Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 61. North America Oncology (Anti-cancer Drugs) Revenue by Country (2018-2024) & (US$ Million)
Table 62. North America Oncology (Anti-cancer Drugs) Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2024) & (K MT)
Table 64. North America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2024-2034) & (K MT)
Table 65. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024) & (K MT)
Table 66. Europe Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024) & (US$ Million)
Table 67. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 68. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 69. Europe Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 70. Europe Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 72. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 73. Europe Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 74. Europe Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 76. Europe Oncology (Anti-cancer Drugs) Revenue by Country (2018-2024) & (US$ Million)
Table 77. Europe Oncology (Anti-cancer Drugs) Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2024) & (K MT)
Table 79. Europe Oncology (Anti-cancer Drugs) Sales Quantity by Country (2024-2034) & (K MT)
Table 80. China Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024) & (K MT)
Table 81. China Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024) & (US$ Million)
Table 82. China Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 83. China Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 84. China Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 85. China Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 87. China Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 88. China Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 89. China Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024) & (K MT)
Table 91. APAC Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024) & (US$ Million)
Table 92. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 93. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 94. APAC Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 95. APAC Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 97. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 98. APAC Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 99. APAC Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Oncology (Anti-cancer Drugs) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 101. APAC Oncology (Anti-cancer Drugs) Revenue by Region (2018-2024) & (US$ Million)
Table 102. APAC Oncology (Anti-cancer Drugs) Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Region (2018-2024) & (K MT)
Table 104. APAC Oncology (Anti-cancer Drugs) Sales Quantity by Region (2024-2034) & (K MT)
Table 105. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Company (2018-2024) & (K MT)
Table 106. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Company (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2018-2024) & (K MT)
Table 108. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Type (2024-2034) & (K MT)
Table 109. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Type (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2018-2024) & (K MT)
Table 112. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Application (2024-2034) & (K MT)
Table 113. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Application (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Country (2018-2024) & (US$ Million)
Table 117. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2018-2024) & (K MT)
Table 119. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity by Country (2024-2034) & (K MT)
Table 120. Roche Company Information
Table 121. Roche Description and Overview
Table 122. Roche Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 123. Roche Oncology (Anti-cancer Drugs) Product and Services
Table 124. Roche Oncology (Anti-cancer Drugs) SWOT Analysis
Table 125. Roche Recent Developments
Table 126. Novartis Company Information
Table 127. Novartis Description and Overview
Table 128. Novartis Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 129. Novartis Oncology (Anti-cancer Drugs) Product and Services
Table 130. Novartis Oncology (Anti-cancer Drugs) SWOT Analysis
Table 131. Novartis Recent Developments
Table 132. Celgene Company Information
Table 133. Celgene Description and Overview
Table 134. Celgene Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 135. Celgene Oncology (Anti-cancer Drugs) Product and Services
Table 136. Celgene Oncology (Anti-cancer Drugs) SWOT Analysis
Table 137. Celgene Recent Developments
Table 138. Amgen Company Information
Table 139. Amgen Description and Overview
Table 140. Amgen Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 141. Amgen Oncology (Anti-cancer Drugs) Product and Services
Table 142. Amgen Oncology (Anti-cancer Drugs) SWOT Analysis
Table 143. Amgen Recent Developments
Table 144. Johnson & Johnson Company Information
Table 145. Johnson & Johnson Description and Overview
Table 146. Johnson & Johnson Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 147. Johnson & Johnson Oncology (Anti-cancer Drugs) Product and Services
Table 148. Johnson & Johnson Oncology (Anti-cancer Drugs) SWOT Analysis
Table 149. Johnson & Johnson Recent Developments
Table 150. GlaxoSmithKline Company Information
Table 151. GlaxoSmithKline Description and Overview
Table 152. GlaxoSmithKline Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 153. GlaxoSmithKline Oncology (Anti-cancer Drugs) Product and Services
Table 154. GlaxoSmithKline Oncology (Anti-cancer Drugs) SWOT Analysis
Table 155. GlaxoSmithKline Recent Developments
Table 156. Eli lilly & Co Company Information
Table 157. Eli lilly & Co Description and Overview
Table 158. Eli lilly & Co Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 159. Eli lilly & Co Oncology (Anti-cancer Drugs) Product and Services
Table 160. Eli lilly & Co Oncology (Anti-cancer Drugs) SWOT Analysis
Table 161. Eli lilly & Co Recent Developments
Table 162. Pfizer Company Information
Table 163. Pfizer Description and Overview
Table 164. Pfizer Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 165. Pfizer Oncology (Anti-cancer Drugs) Product and Services
Table 166. Pfizer Oncology (Anti-cancer Drugs) SWOT Analysis
Table 167. Pfizer Recent Developments
Table 168. Merck & Co. Company Information
Table 169. Merck & Co. Description and Overview
Table 170. Merck & Co. Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 171. Merck & Co. Oncology (Anti-cancer Drugs) Product and Services
Table 172. Merck & Co. Oncology (Anti-cancer Drugs) SWOT Analysis
Table 173. Merck & Co. Recent Developments
Table 174. Sanofi Company Information
Table 175. Sanofi Description and Overview
Table 176. Sanofi Oncology (Anti-cancer Drugs) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 177. Sanofi Oncology (Anti-cancer Drugs) Product and Services
Table 178. Sanofi Oncology (Anti-cancer Drugs) SWOT Analysis
Table 179. Sanofi Recent Developments
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Oncology (Anti-cancer Drugs) Distributors List
Table 183. Oncology (Anti-cancer Drugs) Customers List
Table 184. Oncology (Anti-cancer Drugs) Market Trends
Table 185. Oncology (Anti-cancer Drugs) Market Drivers
Table 186. Oncology (Anti-cancer Drugs) Market Challenges
Table 187. Oncology (Anti-cancer Drugs) Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncology (Anti-cancer Drugs) Product Picture
Figure 2. Global Oncology (Anti-cancer Drugs) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Oncology (Anti-cancer Drugs) Market Share by Type in 2022 & 2034
Figure 4. Blood Cancer Product Picture
Figure 5. Breast Cancer Product Picture
Figure 6. Gastrointestinal Cancer Product Picture
Figure 7. Prostate Cancer Product Picture
Figure 8. Others Product Picture
Figure 9. Global Oncology (Anti-cancer Drugs) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global Oncology (Anti-cancer Drugs) Market Share by Application in 2022 & 2034
Figure 11. Chemotherapy
Figure 12. Targeted Therapy
Figure 13. Immunotherapy (Biologic Therapy)
Figure 14. Hormonal Therapy
Figure 15. Others
Figure 16. Oncology (Anti-cancer Drugs) Report Years Considered
Figure 17. Global Oncology (Anti-cancer Drugs) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 18. Global Oncology (Anti-cancer Drugs) Revenue 2018-2034 (US$ Million)
Figure 19. Global Oncology (Anti-cancer Drugs) Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 20. Global Oncology (Anti-cancer Drugs) Sales Quantity 2018-2034 (K MT)
Figure 21. Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Region (2018-2024)
Figure 22. Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Oncology (Anti-cancer Drugs) Sales Quantity YoY (2018-2034) & (K MT)
Figure 24. North America Oncology (Anti-cancer Drugs) Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Oncology (Anti-cancer Drugs) Sales Quantity YoY (2018-2034) & (K MT)
Figure 26. Europe Oncology (Anti-cancer Drugs) Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Oncology (Anti-cancer Drugs) Sales Quantity YoY (2018-2034) & (K MT)
Figure 28. China Oncology (Anti-cancer Drugs) Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Oncology (Anti-cancer Drugs) Sales Quantity YoY (2018-2034) & (K MT)
Figure 30. APAC Oncology (Anti-cancer Drugs) Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity YoY (2018-2034) & (K MT)
Figure 32. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Oncology (Anti-cancer Drugs) Sales Quantity in 2022
Figure 34. The Top 10 and Top 5 Players Market Share by Oncology (Anti-cancer Drugs) Revenue in 2022
Figure 35. Oncology (Anti-cancer Drugs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 38. Global Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 40. North America Oncology (Anti-cancer Drugs) Revenue Market Share by Company in 2022
Figure 41. North America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Company in 2022
Figure 42. North America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 44. North America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 46. North America Oncology (Anti-cancer Drugs) Revenue Share by Country (2018-2034)
Figure 47. North America Oncology (Anti-cancer Drugs) Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Company in 2022
Figure 51. Europe Oncology (Anti-cancer Drugs) Revenue Market Share by Company in 2022
Figure 52. Europe Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 54. Europe Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 56. Europe Oncology (Anti-cancer Drugs) Revenue Share by Country (2018-2034)
Figure 57. Europe Oncology (Anti-cancer Drugs) Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 59. France Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 63. China Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Company in 2022
Figure 64. China Oncology (Anti-cancer Drugs) Revenue Market Share by Company in 2022
Figure 65. China Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 67. China Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 69. APAC Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Company in 2022
Figure 70. APAC Oncology (Anti-cancer Drugs) Revenue Market Share by Company in 2022
Figure 71. APAC Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 73. APAC Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 75. APAC Oncology (Anti-cancer Drugs) Revenue Share by Region (2018-2034)
Figure 76. APAC Oncology (Anti-cancer Drugs) Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 81. India Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Company in 2022
Figure 83. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue Market Share by Company in 2022
Figure 84. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Oncology (Anti-cancer Drugs) Revenue Share by Country (2018-2034)
Figure 90. Brazil Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Oncology (Anti-cancer Drugs) Revenue (2018-2034) & (US$ Million)
Figure 95. Oncology (Anti-cancer Drugs) Value Chain
Figure 96. Oncology (Anti-cancer Drugs) Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed